<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id><journal-id journal-id-type="iso-abbrev">J. Antimicrob. Chemother</journal-id><journal-id journal-id-type="publisher-id">jac</journal-id><journal-title-group><journal-title>Journal of Antimicrobial Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0305-7453</issn><issn pub-type="epub">1460-2091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7263826</article-id><article-id pub-id-type="pmid">28472323</article-id><article-id pub-id-type="doi">10.1093/jac/dkx118</article-id><article-id pub-id-type="publisher-id">dkx118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>HIV-1 strains belonging to large phylogenetic clusters show accelerated
escape from integrase inhibitors in cell culture compared with viral isolates from
singleton/small clusters</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brenner</surname><given-names>Bluma G.</given-names></name><xref ref-type="aff" rid="dkx118-aff1">1</xref><xref ref-type="corresp" rid="dkx118-cor1"/><!--<email>bluma.brenner@mcgill.ca</email>--></contrib><contrib contrib-type="author"><name><surname>Ibanescu</surname><given-names>Ruxandra-Ilinca</given-names></name><xref ref-type="aff" rid="dkx118-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>Maureen</given-names></name><xref ref-type="aff" rid="dkx118-aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Roger</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="dkx118-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hardy</surname><given-names>Isabelle</given-names></name><xref ref-type="aff" rid="dkx118-aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Routy</surname><given-names>Jean-Pierre</given-names></name><xref ref-type="aff" rid="dkx118-aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kyeyune</surname><given-names>Fred</given-names></name><xref ref-type="aff" rid="dkx118-aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Qui&#x000f1;ones-Mateu</surname><given-names>Miguel E.</given-names></name><xref ref-type="aff" rid="dkx118-aff5">5</xref><xref ref-type="aff" rid="dkx118-aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Wainberg</surname><given-names>Mark A.</given-names></name><xref ref-type="aff" rid="dkx118-aff1">1</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Montreal PHI Cohort Study Group</collab><author-comment><title>&#x02020;</title><p>Members are listed in the Acknowledgements section.</p></author-comment><xref ref-type="author-notes" rid="dkx118-FM1"/></contrib></contrib-group><aff id="dkx118-aff1">
<label>1</label>McGill University AIDS Centre, Lady Davis Institute for Medical Research,
Jewish General Hospital, Montreal, Quebec, Canada</aff><aff id="dkx118-aff2">
<label>2</label>D&#x000e9;partement de Microbiologie et d&#x02019;Immunologie et Centre de Recherche du
Centre hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al (CHUM), Montr&#x000e9;al, Qu&#x000e9;bec, Canada</aff><aff id="dkx118-aff3">
<label>3</label>Centre hospitalier de l&#x02019;Universit&#x000e9; McGill, Montr&#x000e9;al, Qu&#x000e9;bec, Canada</aff><aff id="dkx118-aff4">
<label>4</label>Departments of Molecular Biology and Microbiology, Case Western Reserve
University, Cleveland, OH, USA</aff><aff id="dkx118-aff5">
<label>5</label>Department of Pathology, Case Western Reserve University, Cleveland, OH,
USA</aff><aff id="dkx118-aff6">
<label>6</label>Department of Medicine, Case Western Reserve University, Cleveland, OH,
USA</aff><aff id="dkx118-aff7">
<label>7</label>University Hospitals Translational Laboratory, University Hospitals
Cleveland Medical Center, Cleveland, OH, USA</aff><author-notes><corresp id="dkx118-cor1"><label>*</label>Corresponding author. E-mail:
<email>bluma.brenner@mcgill.ca</email></corresp><fn id="dkx118-FM1"><label>&#x02020;</label><p>Members are listed in the Acknowledgements section.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-05-02"><day>02</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>02</day><month>5</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><!-- oupReleaseDelayRemoved from OA Article (10.1093/jac/dkx118dkx118Original researchHIV-1 strains belonging to large phylogenetic clusters show accelerated
          escape from integrase inhibitors in cell culture compared with viral isolates from
          singleton/small clustersBrennerBluma G.bluma.brenner@mcgill.caIbanescuRuxandra-IlincaOliveiraMaureenRogerMichelHardyIsabelleRoutyJean-PierreKyeyuneFredQui&#x000f1;ones-MateuMiguel E.WainbergMark A.on behalf of the Montreal PHI Cohort Study Group&#x02020;Members are listed in the Acknowledgements section.
        1McGill University AIDS Centre, Lady Davis Institute for Medical Research,
        Jewish General Hospital, Montreal, Quebec, Canada
        2D&#x000e9;partement de Microbiologie et d&#x02019;Immunologie et Centre de Recherche du
        Centre hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al (CHUM), Montr&#x000e9;al, Qu&#x000e9;bec, Canada
        3Centre hospitalier de l&#x02019;Universit&#x000e9; McGill, Montr&#x000e9;al, Qu&#x000e9;bec, Canada
        4Departments of Molecular Biology and Microbiology, Case Western Reserve
        University, Cleveland, OH, USA
        5Department of Pathology, Case Western Reserve University, Cleveland, OH,
        USA
        6Department of Medicine, Case Western Reserve University, Cleveland, OH,
        USA
        7University Hospitals Translational Laboratory, University Hospitals
        Cleveland Medical Center, Cleveland, OH, USA*Corresponding author. E-mail:
bluma.brenner@mcgill.ca&#x02020;Members are listed in the Acknowledgements section.August201701082017020520177282171218319012017172201721320172232017&#x000a9; The Author 2017. Published by Oxford University Press on behalf of
          the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions,
          please email: journals.permissions@oup.com.2017This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/),
which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comAbstract
          Objectives: Viral phylogenetics revealed two patterns of HIV-1 spread among
          MSM in Quebec. While most HIV-1 strains (n&#x02009;=&#x02009;2011) were
          associated with singleton/small clusters (cluster size 1&#x02013;4), 30 viral lineages formed
          large networks (cluster size 20&#x02013;140), contributing to 42% of diagnoses between 2011 and
          2015. Herein, tissue culture selections ascertained if large cluster lineages possessed
          higher replicative fitness than singleton/small cluster isolates, allowing for viral
          escape from integrase inhibitors.
          Methods: Primary HIV-1 isolates from large 20+ cluster
            (n&#x02009;=&#x02009;11) or singleton/small cluster
            (n&#x02009;=&#x02009;6) networks were passagedin
            vitro in escalating concentrations of dolutegravir, elvitegravir and lamivudine
          for 24&#x02013;36&#x02009;weeks. Sanger and deep sequencing assessed genotypic changes under selective
          drug pressure.
          Results: Large cluster HIV-1 isolates selected for resistance to
          dolutegravir, elvitegravir and lamivudine faster than HIV-1 strains forming small
          clusters. With dolutegravir, large cluster HIV-1 variants acquired solitary R263K
            (n&#x02009;=&#x02009;7), S153Y
          (n&#x02009;=&#x02009;1) or H51Y
          (n&#x02009;=&#x02009;1) mutations as the dominant quasi-species within
          8&#x02013;12&#x02009;weeks as compared with small cluster lineages where R263K
            (n&#x02009;=&#x02009;1/6), S153Y (1/6) or WT species (4/6) were
          observed after 24&#x02009;weeks. Interestingly, dolutegravir-associated mutations compromised
          viral replicative fitness, precluding escalations in concentrations beyond 5&#x02013;10&#x02009;nM. With
          elvitegravir, large cluster variants more rapidly acquired first mutations (T66I, A92G,
          N155H or S147G) by week 8 followed by sequential accumulation of multiple mutations
          leading to viral escape (>10&#x02009;&#x003bc;M) by week 24.
          Conclusions: Further studies are needed to understand virological features of
          large cluster viruses that may favour their transmissibility, replicative competence and
          potential to escape selective antiretroviral drug pressure.NIH10.13039/100000002Canadian Institutes for Health ResearchFonds de Recherche du Qu&#x000e9;becR&#x000e9;seau SIDA and FRQ/Research Foundation Flanders202685Genome Canada10.13039/100008762HIV142Case Western Reserve University10.13039/100008136Center for AIDS Research10.13039/100007813P30 AI036219University Hospitals Cleveland Medical Center) --><volume>72</volume><issue>8</issue><fpage>2171</fpage><lpage>2183</lpage><history><date date-type="received"><day>19</day><month>1</month><year>2017</year></date><date date-type="rev-request"><day>17</day><month>2</month><year>2017</year></date><date date-type="rev-recd"><day>21</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of
the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions,
please email: journals.permissions@oup.com.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>),
which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="dkx118.pdf"/><abstract><title>Abstract</title><p>
<bold>Objectives:</bold> Viral phylogenetics revealed two patterns of HIV-1 spread among
MSM in Quebec. While most HIV-1 strains (<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>2011) were
associated with singleton/small clusters (cluster size 1&#x02013;4), 30 viral lineages formed
large networks (cluster size 20&#x02013;140), contributing to 42% of diagnoses between 2011 and
2015. Herein, tissue culture selections ascertained if large cluster lineages possessed
higher replicative fitness than singleton/small cluster isolates, allowing for viral
escape from integrase inhibitors.</p><p>
<bold>Methods:</bold> Primary HIV-1 isolates from large 20+ cluster
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>11) or singleton/small cluster
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>6) networks were passaged<italic>in
vitro</italic> in escalating concentrations of dolutegravir, elvitegravir and lamivudine
for 24&#x02013;36&#x02009;weeks. Sanger and deep sequencing assessed genotypic changes under selective
drug pressure.</p><p>
<bold>Results:</bold> Large cluster HIV-1 isolates selected for resistance to
dolutegravir, elvitegravir and lamivudine faster than HIV-1 strains forming small
clusters. With dolutegravir, large cluster HIV-1 variants acquired solitary R263K
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>7), S153Y
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1) or H51Y
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1) mutations as the dominant quasi-species within
8&#x02013;12&#x02009;weeks as compared with small cluster lineages where R263K
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1/6), S153Y (1/6) or WT species (4/6) were
observed after 24&#x02009;weeks. Interestingly, dolutegravir-associated mutations compromised
viral replicative fitness, precluding escalations in concentrations beyond 5&#x02013;10&#x02009;nM. With
elvitegravir, large cluster variants more rapidly acquired first mutations (T66I, A92G,
N155H or S147G) by week 8 followed by sequential accumulation of multiple mutations
leading to viral escape (&#x0003e;10&#x02009;&#x003bc;M) by week 24.</p><p>
<bold>Conclusions:</bold> Further studies are needed to understand virological features of
large cluster viruses that may favour their transmissibility, replicative competence and
potential to escape selective antiretroviral drug pressure.</p></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>NIH</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap><?release-delay 12|0?></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Canadian Institutes for Health Research</institution></institution-wrap><?release-delay 12|0?></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Fonds de Recherche du Qu&#x000e9;bec</institution></institution-wrap><?release-delay 12|0?></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>R&#x000e9;seau SIDA and FRQ/Research Foundation Flanders</institution></institution-wrap><?release-delay 12|0?></funding-source><award-id>202685</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Genome Canada</institution><institution-id institution-id-type="DOI">10.13039/100008762</institution-id></institution-wrap><?release-delay 12|0?></funding-source><award-id>HIV142</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Case Western Reserve University</institution><institution-id institution-id-type="DOI">10.13039/100008136</institution-id></institution-wrap><?release-delay 12|0?></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Center for AIDS Research</institution><institution-id institution-id-type="DOI">10.13039/100007813</institution-id></institution-wrap><?release-delay 12|0?></funding-source><award-id>P30 AI036219</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>University Hospitals Cleveland Medical Center</institution></institution-wrap><?release-delay 12|0?></funding-source></award-group></funding-group><counts><page-count count="13"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>ART has transformed HIV/AIDS from a deadly pandemic to a treatable and potentially
preventable disease.<xref rid="dkx118-B1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="dkx118-B2" ref-type="bibr"><sup>2</sup></xref>
Expanded access to ART has resulted in 25%&#x02013;50% declines in global epidemics in heterosexual
populations, raising optimism that treatment-as-prevention may arrest the pandemic by 2030
(<ext-link ext-link-type="uri" xlink:href="http://www.unaids.org">www.unaids.org</ext-link>).<xref rid="dkx118-B3" ref-type="bibr"><sup>3&#x02013;7</sup></xref>
The World Health Organization has advanced global &#x02018;90&#x02013;90&#x02013;90&#x02019; targets for 2020 where 90%
living with HIV-1 are informed of their status, 90% of infected individuals receive
antiviral treatment and 90% of those treated achieve viral suppression (<ext-link ext-link-type="uri" xlink:href="http://www.unaids.org">www.unaids.org</ext-link>). HIV-1
guidelines have been revised to meet these objectives, recommending annual HIV testing,
immediate treatment initiation and pre-exposure prophylaxis for high risk populations.<xref rid="dkx118-B1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="dkx118-B3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="dkx118-B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="dkx118-B8" ref-type="bibr"><sup>8&#x02013;16</sup></xref></p><p>As more asymptomatic patients are started on ART, treatment goals will require more robust
and durable first-line regimens to prevent the development and transmission of drug
resistance.<xref rid="dkx118-B17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="dkx118-B18" ref-type="bibr"><sup>18</sup></xref> The mainstay of treatment is two
NRTIs with a third core agent from one of the NNRTI, boosted PI or integrase strand transfer
inhibitor (INSTI) drug classes.<xref rid="dkx118-B19" ref-type="bibr"><sup>19</sup></xref>
In developing countries, rates of virological failure (40%) and transmitted drug resistance
(5%&#x02013;16%) are rising, related to the use of thymidine analogues, particularly stavudine and
zidovudine, and NNRTIs.<xref rid="dkx118-B18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="dkx118-B20" ref-type="bibr"><sup>20&#x02013;24</sup></xref></p><p>Integrase inhibitors, including raltegravir, elvitegravir and dolutegravir, are the
preferred choice for first-line therapy, based on their improved tolerability, dosing (once
daily) and higher barrier to resistance than other antiretroviral drugs (<ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/guidelines">http://aidsinfo.nih.gov/guidelines</ext-link>).<xref rid="dkx118-B25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="dkx118-B26" ref-type="bibr"><sup>26</sup></xref> Resistance to elvitegravir and raltegravir occurs via several
mutational pathways, including: (i) N155H or G140A/G148RHQ pathways conferring raltegravir
and elvitegravir cross-resistance; (ii) T66I or E92Q/G elvitegravir-specific pathways; or
(iii) the Y143R/H/C raltegravir-specific resistance pathway.<xref rid="dkx118-B25" ref-type="bibr"><sup>25</sup></xref> Dolutegravir retains antiviral activity against
HIV-1 variants resistant to raltegravir and elvitegravir.<xref rid="dkx118-B27" ref-type="bibr"><sup>27&#x02013;30</sup></xref> Dolutegravir is far less prone to the development
of resistance in first-line therapy with isolated reported cases of the emergence of R263K,
N155H or G118R.<xref rid="dkx118-B31" ref-type="bibr"><sup>31&#x02013;34</sup></xref> These
substitutions have been shown to arise during<italic>in vitro</italic> cell culture
selection studies.<xref rid="dkx118-B27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="dkx118-B35" ref-type="bibr"><sup>35</sup></xref> Transmitted resistance to integrase inhibitors remains
anecdotal.<xref rid="dkx118-B36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="dkx118-B37" ref-type="bibr"><sup>37</sup></xref></p><p>Disturbingly, HIV-1 epidemics among MSM have not declined in resource-rich nations having
access to the best antiretroviral treatments.<xref rid="dkx118-B38" ref-type="bibr"><sup>38</sup></xref> Viral phylogenetic linkage has revealed that epidemics among MSM
have been sustained by high rates of transmission clustering related in part to episodic
risk effects during highly infectious primary HIV infection (PHI).<xref rid="dkx118-B39" ref-type="bibr"><sup>39&#x02013;46</sup></xref> A shift towards large cluster lineages has
contributed to the growth of HIV epidemics among MSM in Quebec and the Netherlands.<xref rid="dkx118-B47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="dkx118-B48" ref-type="bibr"><sup>48</sup></xref> Whereas half of the HIV-1 epidemic in MSM in Quebec
can be ascribed to 2011 viral lineages leading to singleton/small cluster transmissions
(cluster size 1&#x02013;4), 30 viral variants strains have led to large cluster outbreaks (cluster
size 20&#x02013;140), rising from 13% of new diagnoses in 2004 to 42% of new infections in
2015.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B49" ref-type="bibr"><sup>49</sup></xref> The rise in large 20+ clusters has
offset steady declines in other cluster groups over the last decade.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B49" ref-type="bibr"><sup>49</sup></xref> Transmission clustering has been implicated in the spread of
resistance to thymidine analogues and NNRTIs.<xref rid="dkx118-B21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B50" ref-type="bibr"><sup>50&#x02013;52</sup></xref></p><p>HIV-1 transmission constraints lead to a single monophyletic HIV-1 variant, termed the
transmitted/founder virus, establishing most new infections. There is continued debate as to
whether transmission bottlenecks are stochastic, randomly restricting all viruses, or
selective, favouring specific transmission/founder viruses<xref rid="dkx118-B52" ref-type="bibr"><sup>52&#x02013;55</sup></xref> Observational data from the Montreal PHI cohort
showed that cluster size and the skewed role of 30 founder viruses (1.7% of viral lineages)
in 1200 forward transmissions were not directly related to patient epidemiological factors,
including numbers of reported sexual partnerships and viral load.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref> We postulated that HIV-1 strains associated with
large clusters have unique phenotypic features in reverse transcriptase (RT) and integrase
replicative processes that may have contributed to heightened infectiousness and cluster
burst size.</p><p>To test this hypothesis, tissue culture selections with dolutegravir, elvitegravir and
lamivudine were used to compare the barriers to resistance for viruses derived from 11
patients belonging to 10 large clusters (cluster size 20&#x02013;140) and 6 persons associated with
singleton/small clusters (cluster size 1&#x02013;4). Sanger (population) and next-generation (deep)
sequencing was performed to monitor genotypic changes under selective drug pressure over
36&#x02009;weeks. HIV-1 isolates from large cluster lineages demonstrated a lower genetic barrier to
resistance to dolutegravir, elvitegravir and lamivudine as compared with viruses from
singleton/small cluster networks. However, the rapid acquisition of R263K or S153Y mutations
with dolutegravir compromised viral replicative competence and hindered viral breakthrough.
Taken together, our findings show a selection bias for large cluster viral variants showing
higher replicative fitness under selective drug pressure.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Viral phylogenetic reconstruction of the HIV-1 epidemic in MSM</title><p>Viral phylogenetics was used to reconstruct patterns of HIV-1 spread among newly
diagnosed treatment-naive MSM (<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>4039, 2002&#x02013;15).<xref rid="dkx118-B40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="dkx118-B44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref> HIV-1 genotyping was performed as previously described,
generating partial<italic>pol</italic> sequences that span the viral protease and RT
regions.<xref rid="dkx118-B40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="dkx118-B44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref> Phylogenetic trees were built using MEGA7
integrated software (<ext-link ext-link-type="uri" xlink:href="http://www.megasoftware.net">www.megasoftware.net</ext-link>).<xref rid="dkx118-B44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B50" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="dkx118-B53" ref-type="bibr"><sup>53</sup></xref> Clustering of viral strains was defined by high bootstrap support
(&#x0003e;95%) and short genetic distances (&#x0003c;1.5%). HIV-1 strains from large clusters were
resequenced across the entire integrase region as previously described to compare
clustering patterns across the protease, RT and integrase regions.<xref rid="dkx118-B54" ref-type="bibr"><sup>54</sup></xref></p></sec><sec><title>Isolation of viruses from MSM within large and small cluster groups</title><p>The Fonds de recherche Sant&#x000e9; (FRQS) R&#x000e9;seau SIDA supports a cohort of newly infected
persons with clinical indication of primary infection.<xref rid="dkx118-B55" ref-type="bibr"><sup>55</sup></xref> In this study, HIV-1 strains were isolated from 17
MSM subjects, 11 of whom belonged to 10 large clusters (cluster size 20&#x02013;140) and 6 from
singleton/small cluster transmissions (cluster size 1&#x02013;4). HIV-1 isolates were amplified as
previously described through co-culture of patient CD8-cell-depleted peripheral blood
mononuclear cells with primary human cord blood mononuclear cells (CBMCs).<xref rid="dkx118-B56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="dkx118-B57" ref-type="bibr"><sup>57</sup></xref> HIV-1 strains, integrase natural polymorphisms,
clinical features and GenBank accession numbers are summarized in Table<xref rid="dkx118-T1" ref-type="table">1</xref>.<table-wrap id="dkx118-T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline
natural polymorphisms in the integrase of subtype B HIV-1 isolates used for
<italic>in vitro</italic> selections with elvitegravir, dolutegravir and
lamivudine</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="char" char="" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Lab ID<xref ref-type="table-fn" rid="tblfn1"><sup>a</sup></xref></th><th rowspan="1" colspan="1">Cluster ID (cluster size)<xref ref-type="table-fn" rid="tblfn2"><sup>b</sup></xref></th><th rowspan="1" colspan="1">Visit 1
date</th><th rowspan="1" colspan="1">Months infected (partners)<xref ref-type="table-fn" rid="tblfn3"><sup>c</sup></xref></th><th rowspan="1" colspan="1">CD4 cells/&#x003bc;L<xref ref-type="table-fn" rid="tblfn3"><sup>c</sup></xref></th><th rowspan="1" colspan="1">Integrase
polymorphisms</th><th rowspan="1" colspan="1">GenBank number</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">Large</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14947</td><td rowspan="1" colspan="1">C185.1
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>45)</td><td rowspan="1" colspan="1">01/2014</td><td rowspan="1" colspan="1">2
(1&#x02013;4)</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">E11D, R20K, V31I, S39N, M50I, I72V, S119T, T124N,
G193E, V201I, T218ST,
D286N</td><td rowspan="1" colspan="1">KT988126</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14637</td><td rowspan="1" colspan="1">C185.09
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>45)</td><td rowspan="1" colspan="1">05/2013</td><td rowspan="1" colspan="1">3
(1&#x02013;4)</td><td rowspan="1" colspan="1">550</td><td rowspan="1" colspan="1">E11D, R20K, V31I, S39N, M50I, S119T, T124N, G193E,
V201I, D286N</td><td rowspan="1" colspan="1">KT988125</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14997</td><td rowspan="1" colspan="1">C027.28
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>40)</td><td rowspan="1" colspan="1">02/2014</td><td rowspan="1" colspan="1">3
(1&#x02013;4)</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">E11D, V31I, L101I, S119G, T122I T124A, T125A, F181L,
I203M, K211Q, T218I, D232E, D256E,
D286N</td><td rowspan="1" colspan="1">KT988128</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14969</td><td rowspan="1" colspan="1">C053.16
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>24)</td><td rowspan="1" colspan="1">01/2014</td><td rowspan="1" colspan="1">2
(1&#x02013;4)</td><td rowspan="1" colspan="1">220</td><td rowspan="1" colspan="1">S17N, S24D, D25E, S39C, V201I,
S255Q</td><td rowspan="1" colspan="1">KT988127</td></tr><tr><td rowspan="1" colspan="1">&#x02003;10387</td><td rowspan="1" colspan="1">C099.10
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>35)</td><td rowspan="1" colspan="1">04/2008</td><td rowspan="1" colspan="1">2
(5&#x02013;9)</td><td rowspan="1" colspan="1">580</td><td rowspan="1" colspan="1">V31I, L45Q, I72V, K111E, I113V, T125A, M154I, V201I,
D207N, L234I</td><td rowspan="1" colspan="1">KX714013</td></tr><tr><td rowspan="1" colspan="1">&#x02003;10249</td><td rowspan="1" colspan="1">C099.08&#x0202f;103N
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>34)</td><td rowspan="1" colspan="1">11/2007</td><td rowspan="1" colspan="1">5
(&#x0003e;20)</td><td rowspan="1" colspan="1">1010</td><td rowspan="1" colspan="1">V31I, L45Q, I72V, L101I, K111E, I113V, D207N,
L234I</td><td rowspan="1" colspan="1">KX714014</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12083</td><td rowspan="1" colspan="1">C050.37 G190A
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>140)</td><td rowspan="1" colspan="1">02/2010</td><td rowspan="1" colspan="1">6
(&#x0003e;20)</td><td rowspan="1" colspan="1">1470</td><td rowspan="1" colspan="1">S17N, I72V, I73V, L101I, T124A,
K136Q</td><td rowspan="1" colspan="1">KX714016</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14624</td><td rowspan="1" colspan="1">C050.65 G190A
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>140)</td><td rowspan="1" colspan="1">07/2013</td><td rowspan="1" colspan="1">9
(1&#x02013;4)</td><td rowspan="1" colspan="1">187</td><td rowspan="1" colspan="1">S17N, A23V, L28I, S39C, L101I,
T124A</td><td rowspan="1" colspan="1">KX714018</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12608</td><td rowspan="1" colspan="1">C163.05
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>90)</td><td rowspan="1" colspan="1">05/2011</td><td rowspan="1" colspan="1">4
(1&#x02013;4)</td><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1">E11D, A21T, S39C, L45R, I72V, L101I, G163E,
K244R</td><td rowspan="1" colspan="1">KX714017</td></tr><tr><td rowspan="1" colspan="1">&#x02003;10679</td><td rowspan="1" colspan="1">C075.19
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>21)</td><td rowspan="1" colspan="1">09/2008</td><td rowspan="1" colspan="1">3
(1&#x02013;4)</td><td rowspan="1" colspan="1">1250</td><td rowspan="1" colspan="1">E11D, A21T, L101I, I113V, S119P, T125A, G193E,
D278N</td><td rowspan="1" colspan="1">KX714015</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5331</td><td rowspan="1" colspan="1">C089.01
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>39)</td><td rowspan="1" colspan="1">02/1997</td><td rowspan="1" colspan="1">5
(0)</td><td rowspan="1" colspan="1">191</td><td rowspan="1" colspan="1">E11D, E13D, I72V, L101I, I113V, S119P, T122I,
D256E</td><td rowspan="1" colspan="1">KX714020</td></tr><tr><td colspan="7" rowspan="1">Small</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5326</td><td rowspan="1" colspan="1">C196.02
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>4)</td><td rowspan="1" colspan="1">11/1998</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">E11D,
A21T, L101I, I113V, S119P, T125A, G193E,
D278N</td><td rowspan="1" colspan="1">KX714021</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15366</td><td rowspan="1" colspan="1">C506.01
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>2)</td><td rowspan="1" colspan="1">12/2014</td><td rowspan="1" colspan="1">1
(1&#x02013;4)</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">S17N, I72V, T124A, T206S, N254H, A265V,
S283G</td><td rowspan="1" colspan="1">KT988129</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14514</td><td rowspan="1" colspan="1">S630
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1)</td><td rowspan="1" colspan="1">02/2014</td><td rowspan="1" colspan="1">5
(1&#x02013;4)</td><td rowspan="1" colspan="1">430</td><td rowspan="1" colspan="1">K7R, S17N, M50I, I72V, K111Q, T112V, T124A, T125V,
I220L, Y227F, D256E</td><td rowspan="1" colspan="1">KT988124</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14380</td><td rowspan="1" colspan="1">C309
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1)</td><td rowspan="1" colspan="1">11/2012</td><td rowspan="1" colspan="1">2
(1&#x02013;4)</td><td rowspan="1" colspan="1">730</td><td rowspan="1" colspan="1">R20K, V31I, I84V, T112M, T124N, M154I, V201I,
D278E</td><td rowspan="1" colspan="1">KT988123</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5833</td><td rowspan="1" colspan="1">S347
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1)</td><td rowspan="1" colspan="1">02/2001</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">T112V,
G193E, V201I, S230N</td><td rowspan="1" colspan="1">KT988122</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15600</td><td rowspan="1" colspan="1">C545.01
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>2)</td><td rowspan="1" colspan="1">07/2015</td><td rowspan="1" colspan="1">2
(1&#x02013;4)</td><td rowspan="1" colspan="1">320</td><td rowspan="1" colspan="1">E11D, V31I, A124T, R127K, F181L, V201I, T218I, S230N,
N232D, D256E</td><td rowspan="1" colspan="1">KX714019</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Viruses were isolated from patients participating in
the PHI cohort in Montreal.</p></fn><fn id="tblfn2"><label>b</label><p>Cluster
size was based on phylogenetic analysis of the entire provincial genotyping
programme.</p></fn><fn id="tblfn3"><label>c</label><p>Cohort data, including
estimated time post-infection (months) based on biological assays, the reported
number of partners 3&#x02009;months prior to infection and CD4 counts, were determined at
the first visit.</p></fn></table-wrap-foot></table-wrap></p></sec><sec><title>In vitro selection of HIV-1 strains with reduced susceptibility to antiretroviral
drugs</title><p>Dolutegravir was provided by ViiV Healthcare Ltd (Research Triangle Park, NC, USA).
Elvitegravir was obtained from Gilead Sciences Inc. (Foster City, CA, USA). Lamivudine was
obtained from the NIH AIDS Research and Reference Reagent Program (<ext-link ext-link-type="uri" xlink:href="http://www.aidsreagent.org">http://www.aidsreagent.org</ext-link>). HIV-1 strains from 6 and 11 patients from
singleton/small and large clusters, respectively, were used to infect CBMCs at a similar
moi of 0.1, i.e. 1&#x0205f;&#x000d7;&#x0205f;10<sup>6</sup> TCID<sub>50</sub> per 10&#x0205f;&#x000d7;&#x0205f;10<sup>6</sup> CBMCs, based
on p24 and RT assays.<xref rid="dkx118-B57" ref-type="bibr"><sup>57</sup></xref> Viruses
were serial passaged in CBMCs in the presence of escalating concentrations of
dolutegravir, elvitegravir and/or lamivudine over 24&#x02013;36&#x02009;weeks, as previously
described.<xref rid="dkx118-B58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="dkx118-B59" ref-type="bibr"><sup>59</sup></xref> RT activity in culture
supernatants was quantified weekly to monitor viral replication of individual viral
variants in the presence and absence of drug pressure, adjusting incremental increases in
drug concentrations if RT activity assays exceeded 100&#x0202f;000&#x02009;cpm.<xref rid="dkx118-B58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="dkx118-B59" ref-type="bibr"><sup>59</sup></xref> At each passage, aliquots of cell-free supernatant were stored
at &#x02212;70&#x000b0;C for further genotypic analysis.</p></sec><sec><title>HIV-1 genotyping based on Sanger and deep sequencing</title><p>Genotypic analyses at selected passages evaluated the development of amino acid
substitutions under selective drug pressure, conferring reduced susceptibility to
antiretroviral drugs (i.e. drug resistance mutations). Sanger (population) sequencing of
viral RNA or complementary DNA extracted from culture supernatants was performed as
previously described.<xref rid="dkx118-B54" ref-type="bibr"><sup>54</sup></xref><sup>,</sup><xref rid="dkx118-B59" ref-type="bibr"><sup>59</sup></xref> Deep sequencing was performed using a CLIA/CAP-validated HIV-1
genotyping assay (DEEPGEN&#x02122;HIV) with a &#x0003e;1% cut-off for the detection of minority HIV-1
variants based on the intrinsic error rate of the entire system (0.3%).<xref rid="dkx118-B60" ref-type="bibr"><sup>60</sup></xref> Ultradeep sequencing confirmed the
homogeneity of founder variants, as well as the earliest time to emergence of resistance
to integrase inhibitors.</p></sec><sec><title>Ethics approval</title><p>Ethics approvals for phylogenetic surveillance of the HIV-1 epidemic were obtained from
the Ministry of Health (Quebec) and L&#x02019;Institut national de sant&#x000e9; publique du Qu&#x000e9;bec. Blood
samples from the Montreal primary infection cohort were obtained with informed consent and
ethics approval from recruited individuals from participating hospitals or private
clinics.<xref rid="dkx118-B55" ref-type="bibr"><sup>55</sup></xref></p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Isolation of HIV-1 strains belonging to representative large and singleton/small
clusters</title><p>Viral phylogenetics revealed two predominant patterns of HIV-1 spread among MSM in
Quebec. Half of new infections were associated with singleton/small cluster networks
(cluster size 1&#x02013;4), while 30 viruses (1.7% of viral lineages) resulted in micro-epidemics,
averaging 40 transmissions/cluster (Figure<xref ref-type="fig" rid="dkx118-F1">1</xref>).<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref> Viruses within
both cluster groups were isolated to compare viral escape from antiretroviral
pressure.</p><fig id="dkx118-F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patterns of spread of the HIV-1 epidemic among the MSM population in Quebec
(2002&#x02013;15). Phylogenetic tree analysis ascertained clustering of new infections
genotyped between 2002 and 2015. The frequency of viral lineages (grey) and HIV-1
infections (black) associated with cluster groups, having 1 to 4, 5 to 9, 10 to 19, or
20 to 140 linked transmissions.</p></caption><graphic xlink:href="dkx118f1"/></fig><p>Eleven subtype B viruses belonging to 10 large 20+ clusters and 6 singleton/small
clusters were derived from PHI cohort participants with estimated dates of infection of
3.7&#x0205f;&#x000b1;&#x0205f;0.6&#x02009;months based on Detuned/BED biological assays (Table<xref rid="dkx118-T1" ref-type="table">1</xref>).<xref rid="dkx118-B55" ref-type="bibr"><sup>55</sup></xref>
The 11 large cluster strains were collectively associated with 600 transmissions in
Quebec. The six singleton/small cluster variants included two reference clinical isolates
(5326 and 5833) used in cell culture selections by our laboratory for over a decade. Table
<xref rid="dkx118-T1" ref-type="table">1</xref> shows clinical and genotypic features of
the selected viruses, illustrating that cluster size was not related to the number of
reported sexual partnerships by cohort participants 3&#x02009;months prior to their infection, as
previously reported for the entire MSM cohort.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref></p><p>Viruses associated with the selected 10&#x0202f;20+ large clusters were resequenced across the
integrase-coding regions. Phylogenetic trees showed similar co-clustering patterns across
the integrase region as previously observed across the protease/RT domains. It was,
however, noteworthy that clusters 45, 118 and 185 (cluster size&#x02009;=&#x02009;38, 43 and 45,
respectively) had a shared common branch in the integrase tree although the protease/RT
regions within these three clusters were distinct (Figure<xref ref-type="fig" rid="dkx118-F2">2</xref>).</p><fig id="dkx118-F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Phylogenetic tree analysis shows 10 large clusters sequenced across the protease/RT-
and integrase-coding regions. Note that viruses belonging to cluster 185
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>44), cluster 45
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>38) and cluster 118
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>43) share sequence homology across the
integrase domain.</p></caption><graphic xlink:href="dkx118f2"/></fig></sec><sec><title>In vitro selection of HIV-1 variants resistant to dolutegravir, elvitegravir and
lamivudine</title><p>Clinical isolates from newly infected persons typically use the CCR5 receptor, show
T-cell tropism and do not grow in MT-2 cells. Tissue culture selections were performed
using CBMCs to characterize possible differences in the development of drug resistance to
lamivudine and integrase inhibitors.<xref rid="dkx118-B57" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="dkx118-B61" ref-type="bibr"><sup>61</sup></xref> CBMCs infected with relevant HIV-1 strains (from large or
singleton/small clusters) were serially passaged over the course of 24&#x02013;36&#x02009;weeks in the
presence of increasing concentrations of dolutegravir, elvitegravir, lamivudine or
dolutegravir&#x02009;+&#x02009;lamivudine dual pressure. These drugs are recommended components of choice
in first-line regimens.</p><p>Cell culture selections using large cluster and singleton/small cluster HIV-1 strains
were conducted in parallel under the same conditions. Stepwise drug dose escalations were
based on weekly RT assays, performed for each isolate in the presence and absence of drug.
As illustrated in Figure<xref ref-type="fig" rid="dkx118-F3">3</xref>, viruses in both
cluster groups replicated equally well in the absence of drug pressure. The progress of
viral outgrowth in the presence of stepwise increasing concentrations of inhibitors over
the course of 36&#x02009;weeks, comparing viruses belonging to cluster 185 (14947 and 14637),
cluster 27 (14997) and cluster 53 (14969) and four singleton small cluster lineages (HIV-1
isolates 143809, 14515, 15336 and 5833), is depicted in Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>.</p><fig id="dkx118-F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Levels of viral RT activity following initial infection of CBMCs with large cluster
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>4, filled symbols) and small cluster
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>4, open symbols) viral lineages. Levels of RT
activity remained similar in subsequent serial passage in the absence of drug
pressure.</p></caption><graphic xlink:href="dkx118f3"/></fig><fig id="dkx118-F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Drug resistance selections with lamivudine, elvitegravir, dolutegravir and
dolutegravir&#x02009;+&#x02009;lamivudine. Stepwise increases in drug concentrations under selective
drug pressure were based on levels of RT enzymatic activity at each weekly passage
relative to a no-drug control. The mean weekly drug concentrations were averaged for
the four large cluster viral lineages (black lines) belonging to clusters 27 (14997),
53 (14969) and 185 (14947 and 14637) as compared with four singleton/small cluster
variants (isolates 143809, 14515, 15336 and 5833, grey lines) grown under selective
pressure with lamivudine, elvitegravir, dolutegravir or dolutegravir&#x02009;+&#x02009;lamivudine over
36&#x02009;weeks. The arrows represent viral breakthrough based on the first acquisition of
new resistance mutations presented in Figures<xref ref-type="fig" rid="dkx118-F4">4&#x02013;6</xref>. Regarding lamivudine, one large cluster virus passaged with lamivudine
acquired M184V leading to earlier viral escape by week 16; the remaining three large
clusters developed M184I. DTG, dolutegravir; EVG, elvitegravir; 3TC, lamivudine.</p></caption><graphic xlink:href="dkx118f4"/></fig><p>As illustrated in Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>(a), drug dose
escalations and viral breakthrough, under lamivudine selective pressure, progressed at
faster rates in the case of large cluster lineages as compared with singleton/small
cluster strains. Drug dose escalations with lamivudine in large cluster variants were
associated with the appearance at week 8 of M184V (isolate 14947) or M184I (isolates
14637, 14997 and 14637). The latter isolates shifted from M184I to M184V by weeks 15&#x02013;23,
leading to higher fold resistance (&#x0003e;100-fold) and viral escape. Small cluster isolates
developed resistance more slowly, acquiring M184I infections by week 23 (Figure<xref ref-type="fig" rid="dkx118-F3">3</xref>a). The rapid selection of M184V by isolate 14947
parallels that observed for CXCR4-tropic pNL4.3 reference strain grown in MT-2 cells or
CBMCs. The M184I substitution conferred lower fold resistance, decreased processivity and
replicative fitness than the M184V mutation.<xref rid="dkx118-B62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="dkx118-B63" ref-type="bibr"><sup>63</sup></xref> Large cluster variants showed a more rapid shift from M184I to
M184V when compared with small cluster lineages where selection of M184I was
attenuated.</p><p>Similarly, elvitegravir drug selections performed on four large cluster variants
progressed more rapidly, leading to the first acquisition of the INSTI resistance
mutations T66I (<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>2), N155H
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1) or S147G
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1) at week 8, followed by the further
accumulation of resistance mutations leading to viral escape (&#x0003e;100-fold resistance) at
weeks 23 and 36 (Figure<xref ref-type="fig" rid="dkx118-F3">3</xref>b). In contrast,
elvitegravir selections performed on singleton/small cluster viral lineages were delayed
with the first appearance of T66I as a singlet mutation occurring at week 23 in only two
of four small cluster strains (Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>b).</p><p>Large cluster strains also showed a lower barrier to resistance to dolutegravir with
R263K (<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>3) or S153Y
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1) mutations appearing by week 8 in large cluster
lineages; these mutations were absent in the four small cluster viruses at week 36 (Figure
<xref ref-type="fig" rid="dkx118-F4">4</xref>c). It was, however, noteworthy that the
acquisition of R263K and S153Y had a negative impact on RT enzymatic activity, hindering
escalations in dolutegravir concentrations beyond 5&#x02013;10&#x02009;nM (Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>c). Dual selections with dolutegravir and lamivudine showed the
appearance of resistance in only one large cluster isolate (14947) with the first
appearance of R263K at week 8 preceding the acquisition of M184I/V and M184V at weeks 15
and 23, respectively (Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>d). Drug
concentrations of both drugs could not be increased following the acquisition of
R263K.</p></sec><sec><title>Genotypic analysis of viral outgrowth under dolutegravir and elvitegravir
pressure</title><p>HIV-1 genotypic analysis based on deep sequencing was performed at selected passages to
monitor temporal dynamics of the emergence and accumulation of mutations conferring
resistance to dolutegravir in eight large cluster strains, as compared with six small
cluster variants (Figures<xref ref-type="fig" rid="dkx118-F5">5</xref> and<xref ref-type="fig" rid="dkx118-F6">6</xref>).</p><fig id="dkx118-F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Viral outgrowth of HIV-1 large cluster strains cultured in the presence of increasing
concentrations of dolutegravir. HIV-1 isolates from eight large clusters (cluster size
in parentheses) were cultured in the presence of increasing concentrations of
dolutegravir. Cell-free supernatant was collected at selected time periods and viral
RNA purified and genotyped across the integrase or RT domain. The frequency (%) of
individual amino acid substitutions acquired in the virus population at the designated
weekly passage was determined based on deep sequencing. Cluster 14947 (a and i) was
selected with both dolutegravir and dolutegravir&#x02009;+&#x02009;lamivudine to ascertain the
sequential appearance of R263K and M184V. DTG, dolutegravir; 3TC, lamivudine. An
asterisk indicates Sanger sequencing only.</p></caption><graphic xlink:href="dkx118f5"/></fig><fig id="dkx118-F6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Viral outgrowth of HIV-1 singleton/small cluster strains cultured in the presence of
increasing concentrations of dolutegravir. HIV-1 isolates from six singleton/small
clusters (cluster size in parentheses) were cultured in the presence of increasing
concentrations of dolutegravir. Cell-free supernatant was collected at selected time
periods and viral RNA purified and genotyped across the integrase domain. The
frequency (%) of individual amino acid substitutions acquired in the virus population
at the designated weekly passage was determined based on deep sequencing. DTG,
dolutegravir.</p></caption><graphic xlink:href="dkx118f6"/></fig><p>As depicted in Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>, dolutegravir
selections, performed on large cluster viruses, led to rapid appearance of R263K
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>6/8) or S153Y
(<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1/8) as dominant members of quasi-species within
6&#x02013;8&#x02009;weeks, while H51Y (<italic>n&#x02009;</italic>=<italic>&#x02009;</italic>1/8) appeared by week 12
(Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>). In general, viral outgrowth under
dolutegravir pressure resulted in R263K, S153Y or H51Y as singlet mutations, representing
the dominant quasi-species (&#x0003e;96%) at weeks 24&#x02013;36 based on ultradeep sequencing. The
infrequent appearance of S230R, E157Q, G163R or G59E minority species (&#x0003c;10%) occurred
in some large cluster selections at selected weeks of passage but failed to accumulate
over time. Although isolate 14637, belonging to cluster 185, selected for S153Y (Figure
<xref ref-type="fig" rid="dkx118-F5">5</xref>b), three subsequent dolutegravir
selections using this isolate resulted in R263K as the sole mutation (B. G. Brenner and M.
Oliveira, unpublished results). Isolate 10387 showed the dual appearance of R263K and
S153F as 52% and 10.9% of the quasi-species at week 8, although R263K (99%) became and
remained the dominant quasi-species at week 26 (Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>d).</p><p>There was a delay in the selection of dolutegravir resistance in small cluster as
compared with large cluster lineages (Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>). Four of six small cluster lineages (cluster sizes 1, 1, 1 and 2) failed to
select any resistance to dolutegravir over 36&#x02009;weeks. INSTI-associated mutations were
present at really low frequency as determined by deep sequencing (R263K at 1.1% and Y143H
at 1.6% in 14514 and 14380, respectively) (Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>c and d). The remaining two small clusters (cluster sizes 2 and 4) selected
R263K or S153Y as singleton mutations (Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>a and b).</p><p>Incremental increases in dolutegravir concentrations (beyond 10&#x02009;nM) following acquisition
of R263K, S153Y and H51Y mutations could not be attempted because the pressure on viral
survival was too great based on weekly RT assays (Figures<xref ref-type="fig" rid="dkx118-F4">4</xref>c and<xref rid="dkx118-B5" ref-type="bibr">5</xref>). This
decline in viral replicative fitness under drug pressure is consistent with cell culture
selection studies and integrase enzymatic assays previously performed by our group using
site-directed mutagenesis to insert resistance substitutions into the laboratory HIV-1
pNL4.3 strain.<xref rid="dkx118-B64" ref-type="bibr"><sup>64&#x02013;66</sup></xref> Notably,
isolate 5326 acquiring S153Y showed no further accumulation of mutations after 128&#x02009;weeks
of culture in the presence of dolutegravir (Figure<xref ref-type="fig" rid="dkx118-F5">5</xref>b).</p><p>Cluster 185 isolates 14947 and 14637 harbouring R263K and S153Y at weeks 30 and 34,
respectively, were grown in the absence of dolutegravir pressure for a subsequent 19 and
17&#x02009;weeks, respectively (Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>a and b). The
release of drug pressure failed to lead to a reversion of R263K or S153Y, substantiating
their presence as dominant quasi-species.</p><p>Interestingly, culturing HIV-1 isolate 14947 (cluster 185) with dolutegravir led to the
rapid selection of variants carrying the R263K mutation, as rapidly as M184V selection
with lamivudine (Figure<xref ref-type="fig" rid="dkx118-F4">4</xref>a and d). Again, the
acquisition of M184V/I was faster for large cluster as compared with small cluster
lineages. It is also significant that R263K arose more rapidly than M184V in
dolutegravir&#x02009;+&#x02009;lamivudine dual selections performed with isolate 14947 and that both
mutations can coexist (Figures<xref ref-type="fig" rid="dkx118-F4">4</xref>d and<xref ref-type="fig" rid="dkx118-F5">5</xref>i).</p><p>The development of resistance under elvitegravir pressure proceeded rapidly for large
cluster lineages with a sequential accumulation of multiple mutations along different
resistance pathways (Figure<xref ref-type="fig" rid="dkx118-F7">7</xref>a&#x02013;d). Isolate
14947 acquired T66I and R263K within 8&#x02009;weeks, representing 98.7% and 44.9% of the
quasi-species, respectively (Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>a). By
week 24, the dominant virus coexpressed T66I (99.5%), R263K (98.7%) and E157Q (94.1%)
(Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>a). The second isolate, belonging to
cluster 185 (14637), developed resistance with viruses coexpressing N155H (99.5%), Q95K
(97.5%) and S230R (99.6%) as the dominant quasi-species (Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>b). Isolate 14997 acquired a mixture of different viruses with
T66I, E92G, E157Q, H51Y and/or S147G representing 85.9%, 19.8%, 99.7%, 15.0% and 9.9% of
variants at week 36 (Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>c). Isolate 14969
acquired S147G (92.1%) at week 8 followed by Q148R (99.7%), known to confer high levels of
cross-resistance to elvitegravir and raltegravir (Figure<xref ref-type="fig" rid="dkx118-F7">7</xref>d).<xref rid="dkx118-B25" ref-type="bibr"><sup>25</sup></xref>
The accumulation of mutations along different pathways contributed to viral breakthrough
and &#x0003e;100-fold resistance. Similarly, the acquisition of T66I followed by secondary
mutations, including L74M, Q146K, and G163R, by small cluster viruses contributed to viral
escape by week 24 (Figure<xref ref-type="fig" rid="dkx118-F7">7</xref>e and f).</p><fig id="dkx118-F7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Genotyping analysis based on Sanger and deep sequencing of HIV-1 small cluster
strains cultured in the presence of increasing concentrations of elvitegravir. HIV-1
isolates from four large clusters and two singleton/small clusters were cultured in
the presence of increasing concentrations of elvitegravir. Cell-free supernatant was
collected at selected time periods and viral RNA purified and the RT- and/or
integrase-coding region sequenced using Sanger or deep sequencing as previously
described. The frequency (%) of individual amino acid substitutions acquired in the
virus population at the designated weekly passage was determined based on deep
sequencing. EVG, elvitegravir.</p></caption><graphic xlink:href="dkx118f7"/></fig><p>It was rather surprising that R263K and H51Y did not adversely impact on viral
replicative competence with elvitegravir as observed for dolutegravir (Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>a). Deep sequencing-based genotyping showed T66I
selection occurred prior to R263K followed by E157Q, which may have compensated for the
fitness compromise of R263K (Figure<xref ref-type="fig" rid="dkx118-F6">6</xref>a). The
presence of secondary (accessory) mutations, including T66I, E157Q, G163R and S230R, can
increase levels of resistance and/or viral fitness (Figures<xref ref-type="fig" rid="dkx118-F4">4</xref>b and<xref rid="dkx118-B6" ref-type="bibr">6</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Genetic diversity is the hallmark feature of HIV-1 contributing to the divergent spread of
distinct HIV-1 subtypes and recombinant forms in different regional settings. In Quebec, the
subtype B HIV-1 epidemic among MSM has not declined in the era of potent and simplified ART
and improved treatment-as-prevention strategies. Viral phylogenetic cluster analysis has
shown that half of the subtype B HIV-1 epidemic among MSM can be ascribed to the episodic
genesis and expansion of 30 viral lineages, contributing to 13%, 25% and 42% of new
diagnoses over the periods 2004&#x02013;07, 2008&#x02013;11 and 2012&#x02013;15, respectively.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B67" ref-type="bibr"><sup>67</sup></xref> Here we proposed that the disproportionate contribution of these
30 strains over more than a decade may be related to distinct virological features beyond
the effects of risk behaviour and the high infectiousness of acute/recent stage infection.
Novel findings observed in this study using<italic>in vitro</italic> selections revealed
that HIV-1 large cluster lineages show a lower barrier to resistance when compared with
viruses from singleton/small cluster networks.</p><p>The rapid acquisition of R263K, S153Y or H51Y with dolutegravir was unexpected given the
isolated number of reported cases of resistance in the clinic. Indeed, the appearance of
these dolutegravir-related mutations within 6&#x02013;12&#x02009;weeks using HIV-1 strains from large
clusters was far more rapid than previous studies by our group using laboratory strains
where resistance arises after 20&#x02009;weeks of culture with dolutegravir.<xref rid="dkx118-B68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="dkx118-B69" ref-type="bibr"><sup>69</sup></xref> Furthermore, viruses obtained by site-directed mutagenesis of the
laboratory strain pNL4.3 with R263K or H51Y are severely compromised in their ability to
acquire or coexist with other mutations, such as M184V and T66I.<xref rid="dkx118-B69" ref-type="bibr"><sup>69&#x02013;71</sup></xref> Findings reported herein revealed the emergence
of viral variants coexpressing R263K/M184V and R263K/T66I as dominant (&#x0003e;98%)
quasi-species under selective pressure with dolutegravir&#x02009;+&#x02009;lamivudine and elvitegravir,
respectively. The acquisition of E157Q (94% and 99%) by two viruses (and) coexpressing
T66I/R263K (&#x0003e;98%, isolate 14947) or a mixed T66I (85.9%) and H51Y (15.9%) quasi-species
(isolate 14997) under elvitegravir pressure suggests that E157Q may serve as an accessory
mutation that restores viral replicative fitness and increases resistance.<xref rid="dkx118-B72" ref-type="bibr"><sup>72</sup></xref></p><p>Given the high potency of dolutegravir in the clinic, it has proven difficult to document
and characterize dolutegravir resistance profiles. Cell culture selections performed using
replicatively resilient large cluster variants highlighted novel aspects regarding emergent
resistance to dolutegravir that could not be otherwise ascertained.<xref rid="dkx118-B66" ref-type="bibr"><sup>66</sup></xref> We observed that the rate of appearance of R263K
with dolutegravir was as rapid as that observed for the appearance of M184V with lamivudine.
The emergence of select mutations under dolutegravir pressure, including R263K (AGA&#x02192;AAA or
AGG&#x02192;AAG), G163R (GGA&#x02192;AGA or GGG&#x02192;AGG) and E138K (GAA&#x02192;AAA, GAG&#x02192;AAG), may be related to
APOBEC-mediated G&#x02192;A hypermutation.<xref rid="dkx118-B73" ref-type="bibr"><sup>73</sup></xref>,<xref rid="dkx118-B74" ref-type="bibr"><sup>74</sup></xref> Our
previous studies also showed the development of G118R (GGA&#x02192;AGA) in two patients failing
dolutegravir monotherapy.<xref rid="dkx118-B35" ref-type="bibr"><sup>35</sup></xref> These
patients harboured a rare GGA natural polymorphism (1.5% prevalence) compared with the
majority of clinical viral isolates harbouring GGC (79%) or GGT (18%) glycine motifs where
G118R acquisition would require two point mutations
(<underline>G</underline>G<underline>G</underline>&#x02192;<underline>A</underline>G<underline>A</underline>
or
<underline>G</underline>G<underline>U</underline>&#x02192;<underline>A</underline>G<underline>A</underline>)
or single unfavourable transversions (<underline>G</underline>GG&#x02192;<underline>C</underline>GG
or<underline>G</underline>GU&#x02192;<underline>C</underline>GT), respectively.<xref rid="dkx118-B35" ref-type="bibr"><sup>35</sup></xref> The generation of M184I (ATG&#x02192;ATA)
can also arise from G to A hypermutation although M184V leads to higher fold drug
resistance. Although APOBEC3G-mediated G to A hypermutation may contribute to the
development of drug resistance, it can also inhibit viral replication by driving viruses
into error catastrophe mode.<xref rid="dkx118-B75" ref-type="bibr"><sup>75</sup></xref></p><p>The development of resistance to antiretroviral drug regimens<italic>in vivo</italic> is
predicated on the degree and fitness costs conferred by individual mutations, alone and in
combination with other resistance mutations. Dolutegravir is a drug for which the<italic>in
vitro</italic> acquisition of singlet substitutions, including R263K, S153Y and H51Y,
interfered with further acquisition of secondary resistance mutations.<xref rid="dkx118-B64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="dkx118-B72" ref-type="bibr"><sup>72</sup></xref> These mutations confer minimal resistance (&#x0003c;3-fold) but impose
enormous constraints on viral replicative fitness, decreasing viral infectiousness,
replication capacity, DNA integration and integrase strand-transfer activity.<xref rid="dkx118-B63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="dkx118-B64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="dkx118-B72" ref-type="bibr"><sup>72</sup></xref> The high potency for dolutegravir resulted in EC<sub>50</sub>s of
1&#x02009;nM (0.4&#x02009;ng/ml) and drug concentrations could not be increased beyond 5 to 10&#x02009;nM with R263K
or S153Y to sustain<italic>in vitro</italic> viral replication in CBMCs.<xref rid="dkx118-B63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="dkx118-B64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="dkx118-B76" ref-type="bibr"><sup>76</sup></xref> These<italic>in vitro</italic> drug concentrations are consistent
with therapeutic concentrations of unbound (17&#x02009;ng/mL) and bound (3400&#x02009;ng/mL) dolutegravir in
plasma.<xref rid="dkx118-B77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="dkx118-B78" ref-type="bibr"><sup>78</sup></xref> This contrasts with elvitegravir
selections, such as the cluster 185 isolate, 14947, where acquisition of T66I preceded
R263K, resulting in higher levels of resistance, the acquisition of the compensatory E157Q
and viral escape.<xref rid="dkx118-B72" ref-type="bibr"><sup>72</sup></xref> The combination
of R263K with viruses containing M184I or M184V mutations in dolutegravir&#x02009;+&#x02009;lamivudine
selections further reduced viral replication competence compared with when only single
mutations were present.<xref rid="dkx118-B63" ref-type="bibr"><sup>63</sup></xref> Taken
together, our<italic>in vitro</italic> findings incorporating magnitude of resistance and
fitness costs of individual mutations provide an explanation for the remarkable clinical
success of dolutegravir and bictegravir in recent clinical trials.<xref rid="dkx118-B78" ref-type="bibr"><sup>78&#x02013;80</sup></xref> The high potency of second-generation integrase
inhibitors may prevent or attenuate the development of replicatively fit large cluster
lineages.</p><p>Large cluster outbreaks can contribute to the onward spread of transmitted drug resistance,
principally involving NNRTIs.<xref rid="dkx118-B45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="dkx118-B50" ref-type="bibr"><sup>50</sup></xref> Indeed, the frequency of these resistance mutations in
treatment-naive persons has surpassed that observed in persons failing therapy since
2011.<xref rid="dkx118-B38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="dkx118-B50" ref-type="bibr"><sup>50</sup></xref> Notably, cluster 50 (cluster size
140) and cluster 99-K103N (cluster size 34) remain persistent sub-epidemics harbouring G190A
and K103N, respectively. Genetic differences between viral strains may contribute to their
relative transmissibility, replicative competence and propensity towards the development of
resistance. Our findings show that R263K and S153Y, once acquired, may not revert. The
negative viral fitness costs of these mutations may, however, limit their development and
potential transmissibility. In this regard the prevalence of resistance in patients failing
integrase-based regimens was 8% in Quebec (January 2014&#x02013;April 2016), largely associated with
raltegravir- and elvitegravir-associated resistance mutations (I. Hardy and B. G. Brenner,
unpublished results). Resistance to dolutegravir has, however, been limited to the G118R
case and a novel resistance pathway from a raltegravir-experienced patient harbouring the
N155H mutation.<xref rid="dkx118-B30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="dkx118-B35" ref-type="bibr"><sup>35</sup></xref></p><p>Bottlenecks constrain HIV-1 transmission, such that a single monophyletic founder variant
is responsible for establishing individual infections. Studies have compared the &#x02018;signature&#x02019;
genetic motifs and phenotypic properties of newly transmitted viruses to those of
chronic-stage viruses.<xref rid="dkx118-B81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="dkx118-B82" ref-type="bibr"><sup>82</sup></xref> Transmitted viruses are most often CCR5-tropic, possess signature
leader sequences (codon 11), show less envelope glycosylation and have shorter variable
envelope loops than chronic stage viruses.<xref rid="dkx118-B81" ref-type="bibr"><sup>81</sup></xref><sup>,</sup><xref rid="dkx118-B82" ref-type="bibr"><sup>82</sup></xref> Here, we also show an accelerated development of resistance to
integrase and RT inhibitors on the part of viruses belonging to 10 different large 20+
clusters, perhaps suggesting a potential replicative and/or enzymatic fitness advantage in
the subset of large cluster viruses. Studies are ongoing to ascertain RT and integrase
activity for WT and resistant (R263K or S153Y) cluster 185 isolates, compared with pNL4.3.
Direct study of the infection and replication properties of clinically relevant large
cluster viruses in cell culture may help define distinct features of transmitted viruses and
early events following infection.</p><p>In summary, viral phylogenetic cluster analysis of the HIV-1 epidemic among MSM in Quebec
shows an evolutionary shift towards large cluster lineages. These viruses appear to be able
to overcome severe transmission bottlenecks and circumvent genetic barriers to resistance to
dolutegravir.<xref rid="dkx118-B64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="dkx118-B68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="dkx118-B79" ref-type="bibr"><sup>79</sup></xref> These findings have implications for novel treatment
paradigms under investigation, including simplified dolutegravir&#x02009;+&#x02009;lamivudine dual therapy
and dolutegravir monotherapy regimens.<xref rid="dkx118-B35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="dkx118-B79" ref-type="bibr"><sup>79</sup></xref> Large cluster viruses may assist in assessing as yet unknown
pathways implicated in emergent resistance to new second-generation INSTIs in clinical
trial, including bictegravir and cabotegravir.<xref rid="dkx118-B27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="dkx118-B83" ref-type="bibr"><sup>83</sup></xref><sup>,</sup><xref rid="dkx118-B84" ref-type="bibr"><sup>84</sup></xref></p></sec></body><back><ack><title>Acknowledgements</title><p>The Montreal PHI cohort includes Mario Legault, coordinator and all participating
physicians from Clinique m&#x000e9;dicale L&#x02019;Actuel, Clinique m&#x000e9;dicale Quartier Latin, Centre
hospitalier Universit&#x000e9; de Montr&#x000e9;al, Clinique Roger Leblanc/Opus and Centre hospitalier
Universit&#x000e9; McGill, including Jean-Guy Baril, Louise Charest, Marc-Andr&#x000e9; Charron, Pierre
C&#x000f4;t&#x000e9;, Alexandra de Pokomandy, Serge Dufresne, Claude Fortin, Jason Friedman, Norbert
Gilmore, Emmanuelle Huchet, Marina Klein, Louise Labreque, Richard Lalonde, Roger Leblanc,
Bernard Lessard, Catherine Milne, Marie Munoz, Martin Potter, Danielle Rouleau, Jean-Pierre
Routy, Jason Szabo, R&#x000e9;jean Thomas, Cecile Tremblay, Beno&#x000ee;t Trottier and Sylvie V&#x000e9;zina. We
thank all the patient participants.</p><sec><title>Funding</title><p>This project was supported by the Canadian Institutes for Health Research (CIHR), Fonds
de Recherche du Qu&#x000e9;bec (FRQ) R&#x000e9;seau SIDA and FRQ/Research Foundation Flanders (FWO)
bilateral programme (202685). M. A. W. received a Large-Scale applied research contract in
genomics and personalized healthcare from Genome Canada (HIV142). M. E. Q.-M. was
partially supported by the Case Western Reserve University (CWRU)/University Hospitals
(UH) Center for AIDS Research (P30 AI036219) and by funding from University Hospitals
Cleveland Medical Center (UHCMC) for the University Hospitals Translational Laboratory
(UHTL).</p><p>&#x02003;All funders of research played no decision-making role in the design, execution,
analysis or reporting of the research.</p></sec><sec><title>Transparency declarations</title><p>B. G. B. has received fees for speaking from Gilead Sciences. M. A. W. has received funds
from Gilead Sciences and ViiV Healthcare for speaking and attending symposiums. All other
authors: none to declare.</p><p>All authors have read and approved the text.</p></sec></ack><ref-list><title>References</title><ref id="dkx118-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Montaner</surname><given-names>JS</given-names></name>,<name name-style="western"><surname>Lima</surname><given-names>VD</given-names></name>,<name name-style="western"><surname>Barrios</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Association of highly active antiretroviral therapy coverage, population
viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based
study</article-title>.<source>Lancet</source><year>2010</year>;<volume>376</volume>:
<fpage>532</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">20638713</pub-id></mixed-citation></ref><ref id="dkx118-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Cremin</surname><given-names>I</given-names></name>,<name name-style="western"><surname>Abdullah</surname><given-names>F</given-names></name></person-group>
<etal/>
<article-title>Transformation of HIV from pandemic to low-endemic levels: a public health
approach to combination prevention</article-title>.
<source>Lancet</source><year>2014</year>;<volume>384</volume>:
<fpage>272</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24740087</pub-id></mixed-citation></ref><ref id="dkx118-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name>,<name name-style="western"><surname>Chen</surname><given-names>YQ</given-names></name>,<name name-style="western"><surname>McCauley</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Prevention of HIV-1 infection with early antiretroviral
therapy</article-title>.<source>N Engl J Med</source><year>2011</year>;
<volume>365</volume>:<fpage>493</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">21767103</pub-id></mixed-citation></ref><ref id="dkx118-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>RM</given-names></name>,<name name-style="western"><surname>Lama</surname><given-names>JR</given-names></name>,<name name-style="western"><surname>Anderson</surname><given-names>PL</given-names></name></person-group>
<etal/>
<article-title>Preexposure chemoprophylaxis for HIV prevention in men who have sex with
men</article-title>.<source>N Engl J Med</source><year>2010</year>;
<volume>363</volume>:<fpage>2587</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">21091279</pub-id></mixed-citation></ref><ref id="dkx118-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Insight START Study Group</collab><name name-style="western"><surname>Lundgren</surname><given-names>JD</given-names></name>,<name name-style="western"><surname>Babiker</surname><given-names>AG</given-names></name></person-group>
<etal/>
<article-title>Initiation of antiretroviral therapy in early asymptomatic HIV
infection</article-title>.<source>N Engl J Med</source><year>2015</year>;
<volume>373</volume>:<fpage>795</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26192873</pub-id></mixed-citation></ref><ref id="dkx118-B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grinsztejn</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Hosseinipour</surname><given-names>MC</given-names></name>,
<name name-style="western"><surname>Ribaudo</surname><given-names>HJ</given-names></name></person-group>
<etal/>
<article-title>Effects of early versus delayed initiation of antiretroviral treatment on
clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised
controlled trial</article-title>.<source>Lancet Infect Dis</source><year>2014</year>;
<volume>14</volume>:<fpage>281</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">24602844</pub-id></mixed-citation></ref><ref id="dkx118-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>McCormack</surname><given-names>S</given-names></name>,<name name-style="western"><surname>Dunn</surname><given-names>DT</given-names></name>,<name name-style="western"><surname>Desai</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection
(PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised
trial</article-title>.<source>Lancet</source><year>2016</year>;<volume>387</volume>:
<fpage>53</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26364263</pub-id></mixed-citation></ref><ref id="dkx118-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Labarga</surname><given-names>P.</given-names></name></person-group>
<article-title>New DHHS guidelines recommend antiretroviral therapy to all HIV-infected
persons</article-title>.<source>AIDS Rev</source><year>2012</year>;
<volume>14</volume>:<fpage>154.</fpage><pub-id pub-id-type="pmid">22792582</pub-id></mixed-citation></ref><ref id="dkx118-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>MA</given-names></name>,<name name-style="western"><surname>Aberg</surname><given-names>JA</given-names></name>,<name name-style="western"><surname>Hoy</surname><given-names>JF</given-names></name></person-group>
<etal/>
<article-title>Antiretroviral treatment of adult HIV infection: 2012 recommendations of
the International Antiviral Society-USA panel</article-title>.
<source>JAMA</source><year>2012</year>;<volume>308</volume>:
<fpage>387</fpage>&#x02013;<lpage>402</lpage>.<pub-id pub-id-type="pmid">22820792</pub-id></mixed-citation></ref><ref id="dkx118-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Okwundu</surname><given-names>CI</given-names></name>,<name name-style="western"><surname>Uthman</surname><given-names>OA</given-names></name>,<name name-style="western"><surname>Okoromah</surname><given-names>CA.</given-names></name></person-group>
<article-title>Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in
high-risk individuals</article-title>.<source>Cochrane Database Syst
Rev</source><year>2012</year>; issue<bold>7</bold>:
<fpage>CD007189.</fpage><pub-id pub-id-type="pmid">22786505</pub-id></mixed-citation></ref><ref id="dkx118-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Thigpen</surname><given-names>MC</given-names></name>,<name name-style="western"><surname>Kebaabetswe</surname><given-names>PM</given-names></name>,
<name name-style="western"><surname>Paxton</surname><given-names>LA</given-names></name></person-group>
<etal/>
<article-title>Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in
Botswana</article-title>.<source>N Engl J Med</source><year>2012</year>;
<volume>367</volume>:<fpage>423</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">22784038</pub-id></mixed-citation></ref><ref id="dkx118-B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Abdool Karim</surname><given-names>Q</given-names></name>,<name name-style="western"><surname>Abdool
Karim</surname><given-names>SS</given-names></name>,<name name-style="western"><surname>Frohlich</surname><given-names>JA</given-names></name></person-group>
<etal/>
<article-title>Effectiveness and safety of tenofovir gel, an antiretroviral microbicide,
for the prevention of HIV infection in women</article-title>.
<source>Science</source><year>2010</year>;<volume>329</volume>:
<fpage>1168</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">20643915</pub-id></mixed-citation></ref><ref id="dkx118-B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Donnell</surname><given-names>D</given-names></name>,<name name-style="western"><surname>Baeten</surname><given-names>JM</given-names></name>,<name name-style="western"><surname>Kiarie</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Heterosexual HIV-1 transmission after initiation of antiretroviral therapy:
a prospective cohort analysis</article-title>.<source>Lancet</source><year>2010</year>;
<volume>375</volume>:<fpage>2092</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20537376</pub-id></mixed-citation></ref><ref id="dkx118-B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Z</given-names></name>,<name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name>,<name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name></person-group>
<etal/>
<article-title>Antiretroviral therapy to prevent HIV transmission in serodiscordant
couples in China (2003-11): a national observational cohort study</article-title>.
<source>Lancet</source><year>2013</year>;<volume>382</volume>:
<fpage>1195</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">23206835</pub-id></mixed-citation></ref><ref id="dkx118-B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Granich</surname><given-names>RM</given-names></name>,<name name-style="western"><surname>Gilks</surname><given-names>CF</given-names></name>,<name name-style="western"><surname>Dye</surname><given-names>C</given-names></name></person-group>
<etal/>
<article-title>Universal voluntary HIV testing with immediate antiretroviral therapy as a
strategy for elimination of HIV transmission: a mathematical model</article-title>.
<source>Lancet</source><year>2009</year>;<volume>373</volume>:
<fpage>48</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">19038438</pub-id></mixed-citation></ref><ref id="dkx118-B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bendavid</surname><given-names>E</given-names></name>,<name name-style="western"><surname>Grant</surname><given-names>P</given-names></name>,<name name-style="western"><surname>Talbot</surname><given-names>A</given-names></name></person-group>
<etal/>
<article-title>Cost-effectiveness of antiretroviral regimens in the World Health
Organization&#x02019;s treatment guidelines: a South African analysis</article-title>.
<source>AIDS</source><year>2011</year>;<volume>25</volume>:
<fpage>211</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21124202</pub-id></mixed-citation></ref><ref id="dkx118-B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>We need to use the best antiretroviral drugs worldwide to prevent HIV drug
resistance</article-title>.<source>AIDS</source><year>2016</year>;<volume>30</volume>:
<fpage>2725</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27782967</pub-id></mixed-citation></ref><ref id="dkx118-B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wainberg</surname><given-names>MA</given-names></name>,<name name-style="western"><surname>Zaharatos</surname><given-names>GJ</given-names></name>,
<name name-style="western"><surname>Brenner</surname><given-names>BG.</given-names></name></person-group>
<article-title>Development of antiretroviral drug resistance</article-title>.<source>N
Engl J Med</source><year>2011</year>;<volume>365</volume>:
<fpage>637</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">21848464</pub-id></mixed-citation></ref><ref id="dkx118-B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Llibre</surname><given-names>JM</given-names></name>,<name name-style="western"><surname>Walmsley</surname><given-names>S</given-names></name>,<name name-style="western"><surname>Gatell</surname><given-names>JM.</given-names></name></person-group>
<article-title>Backbones versus core agents in initial ART regimens: one game, two
players</article-title>.<source>J Antimicrob Chemother</source><year>2016</year>;
<volume>71</volume>:<fpage>856</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">26747092</pub-id></mixed-citation></ref><ref id="dkx118-B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>SY</given-names></name>,<name name-style="western"><surname>Jordan</surname><given-names>MR</given-names></name>,<name name-style="western"><surname>Raizes</surname><given-names>E</given-names></name></person-group>
<etal/>
<article-title>HIV-1 drug resistance mutations: potential applications for point-of-care
genotypic resistance testing</article-title>.<source>PLoS
One</source><year>2015</year>;<volume>10</volume>:
<fpage>e0145772.</fpage><pub-id pub-id-type="pmid">26717411</pub-id></mixed-citation></ref><ref id="dkx118-B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>SY</given-names></name>,<name name-style="western"><surname>Blanco</surname><given-names>JL</given-names></name>,<name name-style="western"><surname>Jordan</surname><given-names>MR</given-names></name></person-group>
<etal/>
<article-title>Geographic and temporal trends in the molecular epidemiology and genetic
mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and
sequence-level meta-analysis</article-title>.<source>PLoS
Med</source><year>2015</year>;<volume>12</volume>:
<fpage>e1001810.</fpage><pub-id pub-id-type="pmid">25849352</pub-id></mixed-citation></ref><ref id="dkx118-B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Steegen</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Carmona</surname><given-names>S</given-names></name>,<name name-style="western"><surname>Bronze</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Moderate levels of pre-treatment HIV-1 antiretroviral drug resistance
detected in the first South African national survey</article-title>.<source>PLoS
One</source><year>2016</year>;<volume>11</volume>:
<fpage>e0166305.</fpage><pub-id pub-id-type="pmid">27907009</pub-id></mixed-citation></ref><ref id="dkx118-B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Villabona-Arenas</surname><given-names>CJ</given-names></name>,<name name-style="western"><surname>Vidal</surname><given-names>N</given-names></name>,<name name-style="western"><surname>Guichet</surname><given-names>E</given-names></name></person-group>
<etal/>
<article-title>In-depth analysis of HIV-1 drug resistance mutations in HIV-infected
individuals failing first-line regimens in West and Central Africa</article-title>.
<source>AIDS</source><year>2016</year>;<volume>30</volume>:
<fpage>2577</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">27603287</pub-id></mixed-citation></ref><ref id="dkx118-B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gregson</surname><given-names>J</given-names></name>,<name name-style="western"><surname>Kaleebu</surname><given-names>P</given-names></name>,<name name-style="western"><surname>Marconi</surname><given-names>VC</given-names></name></person-group>
<etal/>
<article-title>Occult HIV-1 drug resistance to thymidine analogues following failure of
first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in
sub Saharan Africa: a retrospective multi-centre cohort study</article-title>.
<source>Lancet Infect Dis</source><year>2017</year>;<volume>17</volume>:
<fpage>296</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">27914856</pub-id></mixed-citation></ref><ref id="dkx118-B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name>,<name name-style="western"><surname>Zanichelli</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Integrase strand transfer inhibitors in the management of HIV-positive
individuals</article-title>.<source>Ann Med</source><year>2014</year>;
<volume>46</volume>:<fpage>123</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24579911</pub-id></mixed-citation></ref><ref id="dkx118-B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Osterholzer</surname><given-names>DA</given-names></name>,<name name-style="western"><surname>Goldman</surname><given-names>M.</given-names></name></person-group>
<article-title>Dolutegravir: a next-generation integrase inhibitor for treatment of HIV
infection</article-title>.<source>Clin Infect Dis</source><year>2014</year>;
<volume>59</volume>:<fpage>265</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">24723281</pub-id></mixed-citation></ref><ref id="dkx118-B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tsiang</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Jones</surname><given-names>GS</given-names></name>,<name name-style="western"><surname>Goldsmith</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase
strand transfer inhibitor with an improved resistance profile</article-title>.
<source>Antimicrob Agents Chemother</source><year>2016</year>;<volume>60</volume>:
<fpage>7086</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">27645238</pub-id></mixed-citation></ref><ref id="dkx118-B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Canducci</surname><given-names>F</given-names></name>,<name name-style="western"><surname>Ceresola</surname><given-names>ER</given-names></name>,
<name name-style="western"><surname>Saita</surname><given-names>D</given-names></name></person-group>
<etal/>
<article-title>
<italic>In vitro</italic> phenotypes to elvitegravir and dolutegravir in primary
macrophages and lymphocytes of clonal recombinant viral variants selected in patients
failing raltegravir</article-title>.<source>J Antimicrob
Chemother</source><year>2013</year>;<volume>68</volume>:
<fpage>2525</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">23798668</pub-id></mixed-citation></ref><ref id="dkx118-B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Canducci</surname><given-names>F</given-names></name>,<name name-style="western"><surname>Ceresola</surname><given-names>ER</given-names></name>,
<name name-style="western"><surname>Boeri</surname><given-names>E</given-names></name></person-group>
<etal/>
<article-title>Cross-resistance profile of the novel integrase inhibitor dolutegravir
(S/GSK1349572) using clonal viral variants selected in patients failing
raltegravir</article-title>.<source>J Infect Dis</source><year>2011</year>;
<volume>204</volume>:<fpage>1811</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21984737</pub-id></mixed-citation></ref><ref id="dkx118-B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>I</given-names></name>,<name name-style="western"><surname>Brenner</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Quashie</surname><given-names>P</given-names></name></person-group>
<etal/>
<article-title>Evolution of a novel pathway leading to dolutegravir resistance in a
patient harbouring N155H and multiclass drug resistance</article-title>.<source>J
Antimicrob Chemother</source><year>2015</year>;<volume>70</volume>:
<fpage>405</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25281399</pub-id></mixed-citation></ref><ref id="dkx118-B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Walmsley</surname><given-names>S</given-names></name>,<name name-style="western"><surname>Baumgarten</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Berenguer</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection
in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE
randomized clinical trial</article-title>.<source>J Acquir Immune Defic
Syndr</source><year>2015</year>;<volume>70</volume>:
<fpage>515</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26262777</pub-id></mixed-citation></ref><ref id="dkx118-B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Raffi</surname><given-names>F</given-names></name>,<name name-style="western"><surname>Rachlis</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Brinson</surname><given-names>C</given-names></name></person-group>
<etal/>
<article-title>Dolutegravir efficacy at 48&#x02009;weeks in key subgroups of treatment-naive
HIV-infected individuals in three randomized trials</article-title>.
<source>AIDS</source><year>2015</year>;<volume>29</volume>:
<fpage>167</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25387312</pub-id></mixed-citation></ref><ref id="dkx118-B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Raffi</surname><given-names>F</given-names></name>,<name name-style="western"><surname>Jaeger</surname><given-names>H</given-names></name>,<name name-style="western"><surname>Quiros-Roldan</surname><given-names>E</given-names></name></person-group>
<etal/>
<article-title>Once-daily dolutegravir versus twice-daily raltegravir in
antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96&#x02009;week results from
a randomised, double-blind, non-inferiority trial</article-title>.<source>Lancet Infect
Dis</source><year>2013</year>;<volume>13</volume>:
<fpage>927</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">24074642</pub-id></mixed-citation></ref><ref id="dkx118-B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Clotet</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Feinberg</surname><given-names>J</given-names></name>,<name name-style="western"><surname>van
Lunzen</surname><given-names>J</given-names></name></person-group>
<etal/>
<article-title>Once-daily dolutegravir versus darunavir plus ritonavir in
antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48&#x02009;week results from the
randomised open-label phase 3b study</article-title>.
<source>Lancet</source><year>2014</year>;<volume>383</volume>:
<fpage>2222</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">24698485</pub-id></mixed-citation></ref><ref id="dkx118-B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Thomas</surname><given-names>R</given-names></name>,<name name-style="western"><surname>Blanco</surname><given-names>JL</given-names></name></person-group>
<etal/>
<article-title>Development of a G118R mutation in HIV-1 integrase following a switch to
dolutegravir monotherapy leading to cross-resistance to integrase
inhibitors</article-title>.<source>J Antimicrob Chemother</source><year>2016</year>;
<volume>71</volume>:<fpage>1948</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">27029845</pub-id></mixed-citation></ref><ref id="dkx118-B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Fransen</surname><given-names>S</given-names></name>,<name name-style="western"><surname>Greenberg</surname><given-names>KS</given-names></name></person-group>
<etal/>
<article-title>Transmission of integrase strand-transfer inhibitor multidrug-resistant
HIV-1: case report and response to raltegravir-containing antiretroviral
therapy</article-title>.<source>Antivir Ther</source><year>2011</year>;
<volume>16</volume>:<fpage>253</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21447875</pub-id></mixed-citation></ref><ref id="dkx118-B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>SD</given-names></name>,<name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>,
<name name-style="western"><surname>Sereti</surname><given-names>I</given-names></name></person-group>
<etal/>
<article-title>Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected
patient</article-title>.<source>Antivir Ther</source><year>2011</year>;
<volume>16</volume>:<fpage>257</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">21447876</pub-id></mixed-citation></ref><ref id="dkx118-B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Charest</surname><given-names>H</given-names></name>,<name name-style="western"><surname>Doualla-Bell</surname><given-names>F</given-names></name>,
<name name-style="western"><surname>Cantin</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>A significant reduction in the frequency of HIV-1 drug resistance in Quebec
from 2001 to 2011 is associated with a decrease in the monitored viral
load</article-title>.<source>PLoS One</source><year>2014</year>;<volume>9</volume>:
<fpage>e109420.</fpage><pub-id pub-id-type="pmid">25295725</pub-id></mixed-citation></ref><ref id="dkx118-B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Leigh Brown</surname><given-names>AJ</given-names></name>,<name name-style="western"><surname>Lycett</surname><given-names>SJ</given-names></name>,<name name-style="western"><surname>Weinert</surname><given-names>L</given-names></name></person-group>
<etal/>
<article-title>Transmission network parameters estimated from HIV sequences for a
nationwide epidemic</article-title>.<source>J Infect Dis</source><year>2011</year>;
<volume>204</volume>:<fpage>1463</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21921202</pub-id></mixed-citation></ref><ref id="dkx118-B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA</given-names></name>,
<name name-style="western"><surname>Roger</surname><given-names>M.</given-names></name></person-group>
<article-title>Phylogenetic inferences on HIV-1 transmission: implications for the design
of prevention and treatment interventions</article-title>.
<source>AIDS</source><year>2013</year>;<volume>27</volume>:
<fpage>1045</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">23902920</pub-id></mixed-citation></ref><ref id="dkx118-B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kouyos</surname><given-names>RD</given-names></name>,<name name-style="western"><surname>von
Wyl</surname><given-names>V</given-names></name>,<name name-style="western"><surname>Yerly</surname><given-names>S</given-names></name></person-group>
<etal/>
<article-title>Molecular epidemiology reveals long-term changes in HIV type 1 subtype B
transmission in Switzerland</article-title>.<source>J Infect
Dis</source><year>2010</year>;<volume>201</volume>:
<fpage>1488</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">20384495</pub-id></mixed-citation></ref><ref id="dkx118-B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bezemer</surname><given-names>D</given-names></name>,<name name-style="western"><surname>van
Sighem</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Lukashov</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Transmission networks of HIV-1 among men who have sex with men in the
Netherlands</article-title>.<source>AIDS</source><year>2010</year>;
<volume>24</volume>:<fpage>271</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">20010072</pub-id></mixed-citation></ref><ref id="dkx118-B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>Future of phylogeny in HIV prevention</article-title>.<source>J Acquir
Immune Defic Syndr</source><year>2013</year>;<volume>63</volume> Suppl 2:
<fpage>S248</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23764643</pub-id></mixed-citation></ref><ref id="dkx118-B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Roger</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Routy</surname><given-names>JP</given-names></name></person-group>
<etal/>
<article-title>High rates of forward transmission events after acute/early HIV-1
infection</article-title>.<source>J Infect Dis</source><year>2007</year>;
<volume>195</volume>:<fpage>951</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17330784</pub-id></mixed-citation></ref><ref id="dkx118-B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Ibanescu</surname><given-names>RI</given-names></name>,
<name name-style="western"><surname>Hardy</surname><given-names>I</given-names></name></person-group>
<etal/>
<article-title>Large cluster outbreaks sustain the HIV epidemic among MSM in
Quebec</article-title>.<source>AIDS</source><year>2017</year>;<volume>31</volume>:
<fpage>707</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">28005684</pub-id></mixed-citation></ref><ref id="dkx118-B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>SB</given-names></name>,<name name-style="western"><surname>Swanstrom</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Kashuba</surname><given-names>AD</given-names></name></person-group>
<etal/>
<article-title>Bottlenecks in HIV-1 transmission: insights from the study of founder
viruses</article-title>.<source>Nat Rev Microbiol</source><year>2015</year>;
<volume>13</volume>:<fpage>414</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">26052661</pub-id></mixed-citation></ref><ref id="dkx118-B47"><label>47</label><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Ibanescu</surname><given-names>RI</given-names></name></person-group>
<etal/> Metamorphosis of the Montreal MSM epidemic: large cluster viruses fuel
transmission. In:<italic>Abstracts of the Twenty-third Conference on Retroviruses and
Opportunistic Infections, Boston, MA, USA, 2016</italic>. Abstract 218. Foundation for
Retrovirology and Human Health, Alexandria, VA, USA.</mixed-citation></ref><ref id="dkx118-B48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bezemer</surname><given-names>D</given-names></name>,<name name-style="western"><surname>Cori</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Ratmann</surname><given-names>O</given-names></name></person-group>
<etal/>
<article-title>Dispersion of the HIV-1 epidemic in men who have sex with men in the
Netherlands: a combined mathematical model and phylogenetic analysis</article-title>.
<source>PLoS Med</source><year>2015</year>;<volume>12</volume>:
<fpage>e1001898.</fpage><pub-id pub-id-type="pmid">26529093</pub-id></mixed-citation></ref><ref id="dkx118-B49"><label>49</label><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Ibanescu</surname><given-names>RI</given-names></name></person-group>
<etal/> Large cluster isolates show facilitated escape from integrase inhibitors. In:
<italic>Abstracts of the Twenty-third Conference on Retroviruses and Opportunistic
Infections, Boston, MA, USA, 2016</italic>. Abstract 480. Foundation for Retrovirology
and Human Health, Alexandria, VA, USA.</mixed-citation></ref><ref id="dkx118-B50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Roger</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Moisi</surname><given-names>DD</given-names></name></person-group>
<etal/>
<article-title>Transmission networks of drug resistance acquired in primary/early stage
HIV infection</article-title>.<source>AIDS</source><year>2008</year>;
<volume>22</volume>:<fpage>2509</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">19005274</pub-id></mixed-citation></ref><ref id="dkx118-B51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Audelin</surname><given-names>AM</given-names></name>,<name name-style="western"><surname>Gerstoft</surname><given-names>J</given-names></name>,<name name-style="western"><surname>Obel</surname><given-names>N</given-names></name></person-group>
<etal/>
<article-title>Molecular phylogenetics of transmitted drug resistance in newly diagnosed
HIV Type 1 individuals in Denmark: a nation-wide study</article-title>.<source>AIDS Res
Hum Retroviruses</source><year>2011</year>;<volume>27</volume>:
<fpage>1283</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21564007</pub-id></mixed-citation></ref><ref id="dkx118-B52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hattori</surname><given-names>J</given-names></name>,<name name-style="western"><surname>Shiino</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Gatanaga</surname><given-names>H</given-names></name></person-group>
<etal/>
<article-title>Characteristics of transmitted drug-resistant HIV-1 in recently infected
treatment-naive patients in Japan</article-title>.<source>J Acquir Immune Defic
Syndr</source><year>2016</year>;<volume>71</volume>:
<fpage>367</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">26428230</pub-id></mixed-citation></ref><ref id="dkx118-B53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Roger</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Stephens</surname><given-names>D</given-names></name></person-group>
<etal/>
<article-title>Transmission clustering drives the onward spread of the HIV epidemic among
men who have sex with men in Quebec</article-title>.<source>J Infect
Dis</source><year>2011</year>;<volume>204</volume>:
<fpage>1115</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21881127</pub-id></mixed-citation></ref><ref id="dkx118-B54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Lowe</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Moisi</surname><given-names>D</given-names></name></person-group>
<etal/>
<article-title>Subtype diversity associated with the development of HIV-1 resistance to
integrase inhibitors</article-title>.<source>J Med Virol</source><year>2011</year>;
<volume>83</volume>:<fpage>751</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21360548</pub-id></mixed-citation></ref><ref id="dkx118-B55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>JP</given-names></name>,<name name-style="western"><surname>Machouf</surname><given-names>N</given-names></name>,<name name-style="western"><surname>Edwardes</surname><given-names>MD</given-names></name></person-group>
<etal/>
<article-title>Factors associated with a decrease in the prevalence of drug resistance in
newly HIV-1 infected individuals in Montreal</article-title>.
<source>AIDS</source><year>2004</year>;<volume>18</volume>:
<fpage>2305</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">15577543</pub-id></mixed-citation></ref><ref id="dkx118-B56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>N</given-names></name>,<name name-style="western"><surname>Perez-Olmeda</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Mateos</surname><given-names>E</given-names></name></person-group>
<etal/>
<article-title>A sensitive phenotypic assay for the determination of human
immunodeficiency virus type 1 tropism</article-title>.<source>J Antimicrob
Chemother</source><year>2010</year>;<volume>65</volume>:
<fpage>2493</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">20947622</pub-id></mixed-citation></ref><ref id="dkx118-B57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>Isolation of drug-resistant mutant HIV variants using tissue culture drug
selection</article-title>.<source>Methods Mol Biol</source><year>2009</year>;
<volume>485</volume>:<fpage>427</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">19020842</pub-id></mixed-citation></ref><ref id="dkx118-B58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Doualla-Bell</surname><given-names>F</given-names></name></person-group>
<etal/>
<article-title>HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in
cell culture</article-title>.<source>AIDS</source><year>2006</year>;
<volume>20</volume>:<fpage>F9</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">16816549</pub-id></mixed-citation></ref><ref id="dkx118-B59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>B</given-names></name>,<name name-style="western"><surname>Turner</surname><given-names>D</given-names></name>,<name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers
cross-resistance to non-nucleoside reverse transcriptase inhibitors</article-title>.
<source>AIDS</source><year>2003</year>;<volume>17</volume>:
<fpage>F1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">12478089</pub-id></mixed-citation></ref><ref id="dkx118-B60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>RM</given-names></name>,<name name-style="western"><surname>Meyer</surname><given-names>AM</given-names></name>,<name name-style="western"><surname>Winner</surname><given-names>D</given-names></name></person-group>
<etal/>
<article-title>Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously
determine susceptibility to protease, reverse transcriptase, integrase, and maturation
inhibitors, as well as HIV-1 coreceptor tropism</article-title>.<source>Antimicrob
Agents Chemother</source><year>2014</year>;<volume>58</volume>:
<fpage>2167</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">24468782</pub-id></mixed-citation></ref><ref id="dkx118-B61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Salomon</surname><given-names>H</given-names></name>,<name name-style="western"><surname>Belmonte</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Nguyen</surname><given-names>K</given-names></name></person-group>
<etal/>
<article-title>Comparison of cord blood and peripheral blood mononuclear cells as targets
for viral isolation and drug sensitivity studies involving human immunodeficiency virus
type 1</article-title>.<source>J Clin Microbiol</source><year>1994</year>;
<volume>32</volume>:<fpage>2000</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">7527427</pub-id></mixed-citation></ref><ref id="dkx118-B62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>R</given-names></name>,<name name-style="western"><surname>Babaoglu</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Lansdon</surname><given-names>EB</given-names></name></person-group>
<etal/>
<article-title>The HIV-1 reverse transcriptase M184I mutation enhances the
E138K-associated resistance to rilpivirine and decreases viral fitness</article-title>.
<source>J Acquir Immune Defic Syndr</source><year>2012</year>;<volume>59</volume>:
<fpage>47</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">21997204</pub-id></mixed-citation></ref><ref id="dkx118-B63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>HT</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>Effect on HIV-1 viral replication capacity of DTG-resistance mutations in
NRTI/NNRTI resistant viruses</article-title>.
<source>Retrovirology</source><year>2016</year>;<volume>13</volume>:
<fpage>31.</fpage><pub-id pub-id-type="pmid">27130466</pub-id></mixed-citation></ref><ref id="dkx118-B64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Han</surname><given-names>YS</given-names></name></person-group>
<etal/>
<article-title>Characterization of the R263K mutation in HIV-1 integrase that confers
low-level resistance to the second-generation integrase strand transfer inhibitor
dolutegravir</article-title>.<source>J Virol</source><year>2012</year>;
<volume>86</volume>:<fpage>2696</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="pmid">22205735</pub-id></mixed-citation></ref><ref id="dkx118-B65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name>,<name name-style="western"><surname>Oliviera</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Veres</surname><given-names>T</given-names></name></person-group>
<etal/>
<article-title>Differential effects of the G118R, H51Y, and E138K resistance substitutions
in different subtypes of HIV integrase</article-title>.<source>J
Virol</source><year>2015</year>;<volume>89</volume>:
<fpage>3163</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">25552724</pub-id></mixed-citation></ref><ref id="dkx118-B66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name>,<name name-style="western"><surname>Osman</surname><given-names>N</given-names></name></person-group>
<etal/>
<article-title>Viral fitness cost prevents HIV-1 from evading dolutegravir drug
pressure</article-title>.<source>Retrovirology</source><year>2013</year>;
<volume>10</volume>:<fpage>22.</fpage><pub-id pub-id-type="pmid">23432922</pub-id></mixed-citation></ref><ref id="dkx118-B67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Gryllis</surname><given-names>C</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>Role of antibody-dependent cellular cytotoxicity and lymphokine-activated
killer cells in AIDS and related diseases</article-title>.<source>J Leukoc
Biol</source><year>1991</year>;<volume>50</volume>:
<fpage>628</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">1940615</pub-id></mixed-citation></ref><ref id="dkx118-B68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Moisi</surname><given-names>D</given-names></name></person-group>
<etal/>
<article-title>The dolutegravir R263K resistance mutation in HIV-1 integrase is
incompatible with the emergence of resistance against raltegravir</article-title>.
<source>AIDS</source><year>2015</year>;<volume>29</volume>:
<fpage>2255</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26372484</pub-id></mixed-citation></ref><ref id="dkx118-B69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name></person-group>
<etal/>
<article-title>Resistance mutations against dolutegravir in HIV integrase impair the
emergence of resistance against reverse transcriptase inhibitors</article-title>.
<source>AIDS</source><year>2014</year>;<volume>28</volume>:
<fpage>813</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24463394</pub-id></mixed-citation></ref><ref id="dkx118-B70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anstett</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Fusco</surname><given-names>R</given-names></name>,<name name-style="western"><surname>Cutillas</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>Dolutegravir-selected HIV-1 containing the N155H and R263K resistance
substitutions does not acquire additional compensatory mutations under drug pressure
that lead to higher-level resistance and increased replicative capacity</article-title>.
<source>J Virol</source><year>2015</year>;<volume>89</volume>:
<fpage>10482</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26246578</pub-id></mixed-citation></ref><ref id="dkx118-B71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anstett</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Oliveira</surname><given-names>M</given-names></name></person-group>
<etal/>
<article-title>Dolutegravir resistance mutation R263K cannot coexist in combination with
many classical integrase inhibitor resistance substitutions</article-title>.<source>J
Virol</source><year>2015</year>;<volume>89</volume>:
<fpage>4681</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">25653436</pub-id></mixed-citation></ref><ref id="dkx118-B72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anstett</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Cutillas</surname><given-names>V</given-names></name>,<name name-style="western"><surname>Fusco</surname><given-names>R</given-names></name></person-group>
<etal/>
<article-title>Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated
dolutegravir resistance and decreases DNA binding activity</article-title>.<source>J
Antimicrob Chemother</source><year>2016</year>;<volume>71</volume>:
<fpage>2083</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27084918</pub-id></mixed-citation></ref><ref id="dkx118-B73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>SY</given-names></name>,<name name-style="western"><surname>Sankaran</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Varghese</surname><given-names>V</given-names></name></person-group>
<etal/>
<article-title>HIV-1 protease, reverse transcriptase, and integrase
variation</article-title>.<source>J Virol</source><year>2016</year>;
<volume>90</volume>:<fpage>6058</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">27099321</pub-id></mixed-citation></ref><ref id="dkx118-B74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>RA</given-names></name>,<name name-style="western"><surname>Moore</surname><given-names>MD</given-names></name>,<name name-style="western"><surname>Hu</surname><given-names>WS</given-names></name></person-group>
<etal/>
<article-title>APOBEC3G induces a hypermutation gradient: purifying selection at multiple
steps during HIV-1 replication results in levels of G-to-A mutations that are high in
DNA, intermediate in cellular viral RNA and low in virion RNA</article-title>.
<source>Retrovirology</source><year>2009</year>;<volume>6</volume>:
<fpage>1</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">19128510</pub-id></mixed-citation></ref><ref id="dkx118-B75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Okada</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Iwatani</surname><given-names>Y.</given-names></name></person-group>
<article-title>APOBEC3G-mediated G-to-A hypermutation of the HIV-1 genome: the missing
link in antiviral molecular mechanisms</article-title>.<source>Front
Microbiol</source><year>2016</year>;<volume>7</volume>:
<fpage>2027.</fpage><pub-id pub-id-type="pmid">28066353</pub-id></mixed-citation></ref><ref id="dkx118-B76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Quashie</surname><given-names>PK</given-names></name>,<name name-style="western"><surname>Mesplede</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Han</surname><given-names>YS</given-names></name></person-group>
<etal/>
<article-title>Biochemical analysis of the role of G118R-linked dolutegravir drug
resistance substitutions in HIV-1 integrase</article-title>.<source>Antimicrob Agents
Chemother</source><year>2013</year>;<volume>57</volume>:
<fpage>6223</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">24080645</pub-id></mixed-citation></ref><ref id="dkx118-B77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Letendre</surname><given-names>SL</given-names></name>,<name name-style="western"><surname>Mills</surname><given-names>AM</given-names></name>,<name name-style="western"><surname>Tashima</surname><given-names>KT</given-names></name></person-group>
<etal/>
<article-title>ING116070: a study of the pharmacokinetics and antiviral activity of
dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive
subjects</article-title>.<source>Clin Infect Dis</source><year>2014</year>;
<volume>59</volume>:<fpage>1032</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">24944232</pub-id></mixed-citation></ref><ref id="dkx118-B78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Laskey</surname><given-names>SB</given-names></name>,<name name-style="western"><surname>Siliciano</surname><given-names>RF.</given-names></name></person-group>
<article-title>Quantitative evaluation of the antiretroviral efficacy of
dolutegravir</article-title>.<source>JCI Insight</source><year>2016</year>;
<volume>1</volume>:<fpage>e90033.</fpage><pub-id pub-id-type="pmid">27882352</pub-id></mixed-citation></ref><ref id="dkx118-B79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>BG</given-names></name>,<name name-style="western"><surname>Wainberg</surname><given-names>MA.</given-names></name></person-group>
<article-title>Clinical benefit of dolutegravir in HIV-1 management related to the high
genetic barrier to drug resistance</article-title>.<source>Virus
Res</source><year>2016</year>; doi:10.1016/j.virusres.2016.07.006.</mixed-citation></ref><ref id="dkx118-B80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sax</surname><given-names>PE</given-names></name>,<name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name>,<name name-style="western"><surname>Crofoot</surname><given-names>G</given-names></name></person-group>
<etal/>
<article-title>Bictegravir versus dolutegravir, each with emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase
2 trial</article-title>.<source>Lancet HIV</source><year>2017</year>;
<volume>4</volume>:<fpage>e154</fpage>&#x02013;<lpage>e160</lpage>.<pub-id pub-id-type="pmid">28219610</pub-id></mixed-citation></ref><ref id="dkx118-B81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sagar</surname><given-names>M.</given-names></name></person-group>
<article-title>HIV-1 transmission biology: selection and characteristics of infecting
viruses</article-title>.<source>J Infect Dis</source><year>2010</year>;
<volume>202</volume> Suppl 2:<fpage>S289</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">20846035</pub-id></mixed-citation></ref><ref id="dkx118-B82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ronen</surname><given-names>K</given-names></name>,<name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name>,<name name-style="western"><surname>Overbaugh</surname><given-names>J.</given-names></name></person-group>
<article-title>HIV transmission biology: translation for HIV prevention</article-title>.
<source>AIDS</source><year>2015</year>;<volume>29</volume>:
<fpage>2219</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">26418086</pub-id></mixed-citation></ref><ref id="dkx118-B83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Margolis</surname><given-names>DA</given-names></name>,<name name-style="western"><surname>Boffito</surname><given-names>M.</given-names></name></person-group>
<article-title>Long-acting antiviral agents for HIV treatment</article-title>.
<source>Curr Opin HIV AIDS</source><year>2015</year>;<volume>10</volume>:
<fpage>246</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">26049949</pub-id></mixed-citation></ref><ref id="dkx118-B84"><label>84</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Whitfield</surname><given-names>T</given-names></name>,<name name-style="western"><surname>Torkington</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>van
Halsema</surname><given-names>C.</given-names></name></person-group>
<article-title>Profile of cabotegravir and its potential in the treatment and prevention
of HIV-1 infection: evidence to date</article-title>.<source>HIV AIDS
(Auckl)</source><year>2016</year>;<volume>8</volume>:
<fpage>157</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">27799824</pub-id></mixed-citation></ref></ref-list></back></article>